Cadence Neuroscience, a medical device company advancing neuromodulation for personalized epilepsy care, today announced Daniel (Dan) Moore will be joining as Independent Board Director.
REDMOND, Wash., Dec. 22, 2025 /PRNewswire-PRWeb/ -- Cadence Neuroscience, a medical device company advancing neuromodulation for personalized epilepsy care, today announced Daniel (Dan) Moore will be joining as Independent Board Director. Moore brings more than 35 years of leadership experience in the medical device industry, with a deep focus on epilepsy treatment and neuromodulation technologies.
Moore currently serves as Chair of CMR Surgical, a U.K.-based robotic surgery company, and as a board member of Neurava, BioHouston, HeroHut, and Purdue's Biomedical Advisory board. He previously served as President and CEO of Cyberonics, where he led the company through a period of transformative growth. Following the merger of Cyberonics and Sorin to form LivaNova, Moore continued as Chairman, further expanding the company's epilepsy neuromodulation business. Earlier in his career, Moore spent nearly two decades at Boston Scientific, holding several senior executive positions. He has also served as Chairman of Brainscope, GI Dynamics, ViewRay, and the Medical Device Manufacturers Association (MDMA), and as a board member of the Epilepsy Foundation, Topera, and Trivascular.
As Independent Director, Moore will collaborate with Cadence's Board and executive leadership team to guide the advancement of the company's Biomarker Targeted Stimulation (BTS) System—an investigational neuromodulation therapy designed to reduce or eliminate seizures in patients with drug-resistant epilepsy.
"Cadence Neuroscience is in an exciting position to truly change the lives of people living with epilepsy," said Dan Moore. "I share their deep commitment to putting patients first and advancing innovative technologies that offer real hope for families affected by epilepsy and other neurological disorders."
Cadence Neuroscience is a clinical-stage company developing a novel neuromodulation therapy for pediatric and adult patients with focal drug-resistant epilepsy. The company's technology is based on research by a Mayo Clinic Neurology and Neurosurgery team, led by Gregory Worrell M.D., Ph.D., lead investigator and Mayo Clinic epileptologist. The therapy utilizes chronic subthreshold cortical stimulation to modulate EEG biomarkers associated with epilepsy to reduce or eliminate seizures. Cadence is currently preparing for clinical studies to support FDA clearance.
"Dan's passion for advancing epilepsy care and his proven leadership in medical innovation make him an incredible addition to our Board," said Kent Leyde, Co-Founder and Chief Executive Officer of Cadence Neuroscience. "He shares our belief that every person living with epilepsy deserves hope, personalized care, and the opportunity for a more independent life. We're honored to have his experience and shared purpose guiding our work."
About Cadence Neuroscience
Cadence Neuroscience is a medical device company developing new therapies for the treatment of epilepsy and other neurological disorders. Founded in 2017 and headquartered in Redmond, Washington, Cadence's core technology was developed at Mayo Clinic and is under clinical evaluation. The company is led by seasoned executives with extensive backgrounds in neural implant product development and clinical studies. For more information, visit cadenceneuro.com.
Mayo Clinic and Dr. Worrell have a financial interest in the technology referenced in this news release. Mayo Clinic will use any revenue it receives to support its not-for-profit mission in patient care, education, and research.
Related Links:
https://www.bostonscientific.com/
https://morphicmedical.com/ (formerly GI Dynamics)
https://www.medicaldevices.org/
https://businessdevelopment.mayoclinic.org/
Media Contact:
Alysa Wood
(425) 298-3184
[email protected]
Media Contact
Alysa Wood, Cadence Neuroscience, 1 (425) 298-3184, [email protected], https://cadenceneuro.com/
SOURCE Cadence Neuroscience
Share this article